This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Doñate, F. Articles by Mazar, A. P. PubMed PubMed Citation Articles by Doñate, F. Articles by Mazar, A. P.

Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH₂): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth

Authors' Affiliations: ¹ Attenuon, LLC, San Diego, California; ² Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; ³ Fox Chase Cancer Center, Philadelphia, Pennsylvania; and ⁴ D.E. Shaw Research, New York, New York

Requests for reprints: Andrew P. Mazar, Attenuon, LLC, 10110 Sorrento Valley Road, Suite A, San Diego, CA 92121. Phone: 858-558-4111; Fax: 858-558-4781; E-mail: mazar{at}attenuon.com.

Purpose: ATN-161 (Ac-PHSCN-NH₂) is an integrin-binding peptide that is currently in phase II trials in cancer patients. This peptide has been shown to have antitumor activity in a number of different preclinical models.

Experimental Design: In this study, we examined the binding, biodistribution, and dose and biomarker response of ATN-161 in several animal models.

Results: ATN-161 bound to the β subunit of a number of different integrins implicated in tumor growth and progression, which depended on its cysteine thiol. The peptide had antiangiogenic activity in the Matrigel plug model, and this activity could be reversed by inhibitors of protein kinase A, an effector of ₅β₁-dependent angiogenesis. A labeled analogue of ATN-161, ATN-453, localized to neovessels but not to preexisting vasculature in vivo. The half-life of the peptide when localized to a tumor was much longer than in plasma. Dose-response studies in the Matrigel plug model of angiogenesis or a Lewis lung carcinoma model of tumor growth showed a U-shaped dose-response curve with 1 to 10 mg/kg given thrice a week, being the optimal dose range of ATN-161. Two additional pharmacodynamic models of angiogenesis (dynamic contrast-enhanced magnetic resonance imaging and measurement of endothelial cell progenitors) also revealed U-shaped dose-response curves.

Conclusions: The presence of a U-shaped dose-response curve presents a significant challenge to identifying a biologically active dose of ATN-161. However, the identification of biomarkers of angiogenesis that also exhibit this same U-shaped response should allow the translation of those biomarkers to the clinic, allowing them to be used to identify the active dose of ATN-161 in phase II studies.